Market Research Future (MRFR’s) latest study reveals that the global market for human growth hormone will surge at an impressive CAGR of 7.50% during the review period (2018-2023). Growth hormone deficiency falls under the list of endocrine conditions. Growth hormone deficiency is prevalent across the globe and the reasons for the condition usually vary from person to person. Though the condition is rare, its prevalence rate has increased to a noteworthy level in recent times. In many cases, brain injury has been identified as a primary cause of growth hormones deficiency. Low level of growth hormone secretion can lead to altered body composition, osteoporosis, insulin resistance, lipid abnormalities, reduced energy levels, and reduced muscle strength. Low growth hormone secretion is usually an issue that starts at a young age and if not addressed promptly, may have major implications in later stages of life.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6494
Today, the level of awareness about the condition is much higher than in the past. Modern parents show higher vigilance in monitoring their offspring’s overall physical development and are quick to react to any anomaly they observe. Increasing awareness about endocrine disorders is reflecting favourably on the global human growth hormone market. Demand for growth hormones has increased substantially. Moreover, arrival of more effective hormones has had a positive impact on the popularity of such medical products.
Global Human Growth Hormone Market: Segmental Analysis
MRFR’s report offers a thorough segmental analysis of the market on the basis of brand, route of administration, application, and distribution channel. By brand, the market has been segmented into norditropin, genotropin, mumatrope, sainzen, omnitrope and others. Among these, the norditropin segment is holds the dominant share of the market and is expected retain its positing over 2023. In 2017, the segment stood at USD 1494.98 Mn and is projected to witness a double-digit CAGR during the forecast period. By application, the market has been segmented into growth hormone deficiency, idiopathic short stature, small for gestational age, turner syndrome,
prader-willi syndrome and others. The growth hormone deficiency segment accounts for the largest share of the market and is expected to exhibit a CAGR of 7.07% during the assessment period. By route of administration, the market has been segmented into subcutaneous, intramuscular, intravenous and oral. The subcutaneous segment currently holds the leading position and accounted for more than two-third share of the market in 2017. The segment is expected to remain highly attractive throughout the assessment period. By distribution channel, the market is segmented into hospital pharmacies, clinics, retail pharmacies and e-commerce websites. The hospital pharmacies segment represented close to 40% market share in 2017 and is project to witness a health growth over the next couple of years.
Global Human Growth Hormone Market: Regional Analysis
The report covers the human growth hormone market across Americas, Asia Pacific (APAC), Europe, the Middle East & Africa. The market is Americas is expected to remain highly lucrative during the review period. In 2017, Americas commanded over 49.18% share of the market and is expected to maintain its dominant position in 2018 and beyond. Factors such as the increasing prevalence of growth hormone deficiency, high healthcare spending, and widespread awareness among consumers are partly driving the growth of the market in the region. Americas is followed by Europe and APAC respectively. Sales of human growth hormones have also picked up pace in GCC countries, which brings MEA under the radar of market players operating on a global level.
Global Human Growth Hormone Market: Competitive Landscape
Some of leading market players profiled in the report include Pfizer Inc., Novo Nordisk A/S, Anhui Anke Biotechnology Co. Ltd., Eli Lilly and Company, GeneScience Pharmaceuticals Co. Ltd., Genetech Inc., Novartis AG, Biopartners GmbH, Zhongshan Hygene Biopharm Co. Ltd., Merck KGaA, Ipsen S.A. and Lifetech Labs
FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/human-growth-hormone-market-6494
No comments:
Post a Comment